Skip Navigation


QJM Advance Access originally published online on January 17, 2005
QJM 2005 98(2):75-86; doi:10.1093/qjmed/hci013
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
98/2/75    most recent
hci013v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bamford, K.B.
Right arrow Articles by Shaw, R.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bamford, K.B.
Right arrow Articles by Shaw, R.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

QJM vol. 98 no. 2 © Association of Physicians 2005; all rights reserved.

Review

Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust

K.B. Bamford1, S. Wood2 and R.J. Shaw3

From the 1Department of Infectious Diseases and Microbiology, Imperial College, and Division of Microbiology, Hammersmith Hospitals NHS Trust, London, 2Universal Safety Consultants Ltd, London, and 3Medical Director's Office, Hammersmith Hospital, London, UK

Conducting gene therapy clinical trials with genetically modified organisms as the vectors presents unique safety and infection control issues. The area is governed by a range of legislation and guidelines, some unique to this field, as well as those pertinent to any area of clinical work. The relevant regulations covering gene therapy using genetically modified vectors are reviewed and illustrated with the approach taken by a large teaching hospital NHS Trust. Key elements were Trust-wide communication and involvement of staff in a pro-active approach to risk management, with specific emphasis on staff training and engagement, waste management, audit and record keeping. This process has led to the development of proposed standards for clinical trials involving genetically modified micro-organisms.

Address correspondence to Dr K.B. Bamford, Division of Microbiology, Hammersmith Hospitals NHS Trust, Du Cane Road, London W12 0NN. e-mail: k.bamford{at}imperial.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding
Gene therapy: targeting the myocardium
Heart, January 1, 2008; 94(1): 89 - 99.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, February 26, 2005; 330(7489): 488 - 488.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.